Section 1: Fluid and Imaging Markers of Pathologies associated with Alzheimer Disease or other Related Dementias.- Chapter 1: Fluid and Imaging Markers of Amyloid Pathology.- Chapter 2: Fluid Markers of Tau Pathology.- Chapter 3: Fluid and Imaging Markers of Synuclein Pathology.- Chapter 4: Fluid and Imaging Markers of Synaptic Injury.- Chapter 5: Fluid Markers of Neuronal and Axonal Injury.- Chapter 6: Fluid and Imaging Markers of Glial Reactivity.- Chapter 7: Fluid and Imaging Markers of Vascular Disease.
- Section 2: Fluid and Imaging Markers of Neurodegenerative Disorders.- Chapter 8: Fluid and Imaging Markers of Alzheimer Disease.- Chapter 9: Fluid and Imaging Markers of Frontotemporal Lobar Degeneration.- Chapter 10: Fluid and Imaging Markers of Lewy body dementias.- Chapter 11: Fluid and Imaging Markers of Huntington's Disease.- Section 3: Single and Integrated Omics Studies in Biomarker Discovery.- Chapter 12: Proteomics for Novel Biomarker and Drug Target Discovery in Alzheimer Disease.- Chapter 13: Genomics and Transcriptomics of Alzheimer Disease.
- Section 4: Biomarkers in Clinical and Translational Alzheimer Disease Research.- Chapter 14: Biomarkers in Clinical Trials of Alzheimer Disease: An Overview.- Chapter 15: Biomarkers As Outcome Measures in Clinical Trials of Alzheimer Disease.- Chapter 16: Impact of Pre-analytical Factors on Fluid Biomarker Measurements in Alzheimer Disease.- Chapter 17: Mild Behavioral Impairment and Alzheimer's Disease Biomarker Sample Enrichment for Clinical Trial Screening and Recruitment.- Section 5: Future Directions in Biomarker Research.- Chapter 18: Extracellular Vesicles as Biomarkers in Alzheimer Disease and Related Dementias.- Chapter 19: Sex Differences in Alzheimer Disease-Related Biomarkers and Dementia Risk.
- Chapter 20: Imaging Markers of Amyloid and Tau.- Chapter 21: Novel Markers of Brain Endothelial Injury.- Epilogue: Expert Commentary on Future Directions or Epilogue: Sex/racial differences, standardization, and TDP-43.